Skip to main content

Coronavirus (COVID-19) Updates: Visitation Policies (New! 11.25.20) | How We're Keeping You Safe | Latest COVID Information

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

CLYM17097 / S1608 / Paul Barr

Research Question:
What are the good and bad effects of using TGR-1202 and lenalidomide in combination with the antibody, obinutuzumab?

Basic Study Information

Purpose:
This randomized phase II trial studies how well obinutuzumab with or without umbralisib, lenalidomide, or combination chemotherapy work in treating patients with grade I-IIIa follicular lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with obinutuzumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Umbralisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, prednisone, and bendamustine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving obinutuzumab with or without umbralisib, lenalidomide, or combination chemotherapy will work better in treating patients with grade I-IIIa follicular lymphoma.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT03269669?term=S1608&rank=1
Study Reference #: CLYM17097

Lead Researcher (Principal Investigator)

Lead Researcher:  Paul Barr

Study Contact Information

Study Coordinator: Jessica Mackowiak
Email: jessica_ellis@urmc.rochester.edu

Additional Study Details

Return to Search